A hearing will get underway in Delaware later today in the latest phase of GSK’s attempts to defend itself from allegations that its Zantac drug caused cancer in patients. The three-day hearing ...

Shares in GSK fell around 9% this morning after a judge in a Delaware court gave the green light for tens of thousands of lawsuits claiming harm by gastrointestinal drug Zantac to proceed to trial.

One risk that could dent GSK’s future profits is further legal action connected to its Zantac drug or any others. Another is any sustained negative effect from 2 April’s US tariffs announcement.

[1] The real question facing the court would be: should they have known (and undertaken further research) an allegation seemingly hovering around the Zantac cases. We won’t have definitive answers ...

Objective: To identify and evaluate the quality of evidence supporting prophylactic use of treatments for stress ulcers and upper gastrointestinal bleeding. Stress ulcers, erosions of the stomach ...

New Delhi: Amid continued global concerns over the presence of N-nitrosodimethylamine (NDMA) impurities in ranitidine, the Drugs Technical Advisory Board (DTAB) has recommended a fresh, in-depth ...

A comprehensive literature review was conducted for all medications on the formulary of Bedlam Clinic, a free evening clinic for the medically indigent or working poor, offered by the University ...

Following the withdrawal of ranitidine, we selected subcutaneous esomeprazole as an alternative.2–4 We audited its introduction and found it to be well tolerated, but encountered circumstances where ...